大疱性类天疱疮(BP)是一种主要影响老年人的自身免疫性水疱疾病。人类白细胞抗原(HLA)系统被认为是参与BP发展的遗传因素之一。主要组织相容性复合体II类之间的联系,特别是HLA-DQA1,血压仍然没有定论。这篇综述的目的是发现BP和HLA-DQA1等位基因之间的潜在关联,确定与发生BP的风险增加或减少相关的HLA-DQA1等位基因,并突出了未来研究的文献空白。使用系统审查和荟萃分析(PRISMA)指南的首选报告项目进行文献综述。使用的数据库包括PubMed/MEDLINE,谷歌学者,Embase,科克伦图书馆仅包括以英语编写并在2000年之后进行的研究,该研究调查了人类受试者中HLA-DQA1与BP之间的关联。根据研究中提供的数据计算赔率比,并使用ReviewManager(CochraneCollaboration,伦敦,英国)和MetaXL(EpiGearInternationalPtyLtd.,昆士兰,澳大利亚)软件。系统审查发现了五项合格的研究,全部纳入荟萃分析.结果显示HLA-DQA1*05:05位点的BP几率增加(比值比(OR)=2.25;95%置信区间(CI)=1.80,2.80),HLA-DQA1*02:01位点的BP几率降低(OR=0.50;95%CI=0.36,0.70)。需要进一步的研究来证实这些发现,并探索BP患者个性化医疗方法的潜在临床意义。
Bullous pemphigoid (BP) is an autoimmune blistering disease that mainly affects the elderly. The human leukocyte antigen (HLA) system is believed to be one of the genetic factors involved in the development of BP. The connection between major histocompatibility complex class II, specifically HLA-DQA1, and BP remains inconclusive. The objective of this
review is to find potential associations between BP and HLA-DQA1 alleles, identify the HLA-DQA1 alleles associated with an increased or decreased risk of developing BP, and highlight literature gaps for future research. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were used to conduct a literature
review. Databases used included PubMed/MEDLINE, Google Scholar, Embase, and Cochrane Library. Only studies written in English and conducted after 2000 that investigated the association between HLA-DQA1 and BP in human subjects were included. Odds ratios were calculated from the data provided in the studies, and a meta-analysis was conducted using
Review Manager (The Cochrane Collaboration, London, United Kingdom) and MetaXL (EpiGear International Pty Ltd., Queensland, Australia) software. The systematic
review found five eligible studies, and all were included in the meta-analysis. Results show an increased odds for BP in the HLA-DQA1*05:05 loci (odds ratio (OR) = 2.25; 95% confidence interval (CI) = 1.80, 2.80) and decreased odds for BP in the HLA-DQA1*02:01 loci (OR = 0.50; 95% CI = 0.36, 0.70). Further research is needed to confirm these findings and explore the potential clinical implications for personalized medicine approaches in BP patients.